Your browser doesn't support javascript.
loading
Moderate ischemic mitral regurgitation in ischemic heart disease: to operate or not? A meta-analysis.
Alsuayri, Razan A; Alassiri, Abdullah K; Awad, Ahmed K; Faleh, Mohammed N; Baqays, Rasha T; Porqueddu, Massimo.
Afiliación
  • Alsuayri RA; Batterjee Medical College for Sciences and Technology, Jeddah, Saudi Arabia.
  • Alassiri AK; Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Awad AK; Faculty of Medicine, Ain-Shams University, Cairo, Egypt - ahmedkawad@gmail.com.
  • Faleh MN; College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
  • Baqays RT; Department of Cardiac Surgery, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.
  • Porqueddu M; Department of Cardiac Surgery, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.
Article en En | MEDLINE | ID: mdl-38445846
ABSTRACT

INTRODUCTION:

Deciding whether to perform coronary artery bypass grafting (CABG) alone or in combination with mitral valve repair is a common dilemma encountered by surgeons when treating patients with ischemic mitral regurgitation, a common condition related to coronary artery disease. Although ischemic mitral regurgitation after CABG has been linked to unfavorable results, the benefits of including mitral valve repair are still unknown. This discrepancy led us to undertake a systematic review and meta-analysis to determine whether combining CABG with mitral valve surgery leads to better clinical results than CABG alone. EVIDENCE ACQUISITION Studies comparing the results of CABG versus CABG with mitral valve replacement were searched in the databases of PubMed and Google Scholar. There were six randomized clinical trials included in this study. EVIDENCE

SYNTHESIS:

We analyzed 852 patients' data. There were no significant variations between patients who acquired CABG alone or CABG+(MVR) in terms of their risk of death at one year, stroke, atrial fibrillation, or hospitalization for heart failure. For recurrent/residual mitral regurgitation; it revealed an RR=5.42, 95% CI, 0.77 to 37.98, and a P-value of =0.065. According to the analysis of study heterogeneity, no apparent heterogeneity was identified in the outcomes of death after one year, stroke, atrial fibrillation, or hospitalization for heart failure. However, the outcome of recurrent or residual mitral regurgitation showed significant variation (I2=66%).

CONCLUSIONS:

Patients who underwent CABG alone versus CABG plus MVR did not differ significantly from one another. However, the comparison of CABG alone with CABG plus MVR underlines the need for customized treatment plans based on the unique characteristics of each patient.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Cardiovasc Surg (Torino) Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Cardiovasc Surg (Torino) Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita